Abdulrahman Al Raizah: Mitapivat for Transfusion-Dependent Thalassemia – The ENERGIZE-T Phase 3 Trial
Abdulrahman Al Raizah, Mortality and Morbidity Meeting Lead, Adult Hematology Division at Ministry of National Guard Health Affairs (MNGHA), shared a post on LinkedIn about a recent article he and his colleagues co-authored, published in The Lancet, adding:
“Just published in The Lancet, the ENERGIZE-T Phase 3 trial evaluated mitapivat in transfusion-dependent alpha and beta-thalassaemia, showing significant reductions in transfusion burden and cases of transfusion independence.
Following last year’s published ENERGIZE Phase 3 trial in non-transfusion-dependent thalassaemia, this second milestone underscores the clinical potential of oral pyruvate kinase activators across the full spectrum of thalassaemia management.
Participating in both the ENERGIZE trial last year and the ENERGIZE-T trial this year reflects the driving role of Ministry of National Guard Health Affairs (MNGHA) and King Abdullah International Medical Research Center (KAIMRC) in advancing global clinical research in hemoglobinopathies.
Sincere thanks to Prof Ahmed Alaskar and the entire KAIMRC team for their support—and above all, to the patients whose trust makes this work possible.
Privileged to have served as the site Principal Investigator for both trials.”
Title: Efficacy and safety of mitapivat in adults with transfusion-dependent α-thalassaemia or β-thalassaemia (ENERGIZE-T): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial
Authors: Maria Domenica Cappellini, Sujit Sheth, Ali Taher, Hanny Al-Samkari, Ali Bülent Antmen, David Beneitez, Giovanna Cannas, Thomas Coates, Lauren Czapla, Jayme L Dahlin, Jeremie H Estepp, Elizabeth Feenstra, Pencho Georgiev, Sarah Gheuens, Gavrielle M Price, Andreas Glenthøj, Khaled M Musallam, Kareem Osman, John B Porter, Hui Shao, Katrin Uhlig, Eduard J van Beers, Vip Viprakasit, Kevin H M Kuo, Antonis Kattamis
Stay updated on all scientific advances with Hemostasis Today.
-
Sep 12, 2026, 16:14Pierre F. Saboret: IPF and Long Term Prognosis Thrombosis and Haemostasis
-
Sep 12, 2026, 15:50Dalip Kumar: ED to Mental Health Unit Transfer Completeness Following Intentional Overdose
-
Sep 12, 2026, 15:15Ali Saad Al-shammari: LAAC vs Medical Therapy for Stroke Prevention in AF
-
Sep 12, 2026, 14:33A New Approach to Transfusion Support – ISBT
-
Sep 12, 2026, 14:32Aref Bin Abdulhak: Diminishing Benefit of IVUS-Guided PCI Over Time – A 23-RCT Meta-Analysis
-
Sep 12, 2026, 14:27Advice to My Younger Self Living With VWD – Haemophilia Foundation Australia
-
Sep 12, 2026, 14:18Arun V J: A Love Letter to Transfusion Medicine Through Greek Mythology
-
Sep 12, 2026, 14:09Mick Thompson: 2026 AHA/ACC Pulmonary Embolism Guidelines and the Evolving Role of Mechanical Thrombectomy
-
Sep 12, 2026, 14:05Chokri Ben Lamine: Ruxolitinib Safety – Practical Reminders for Hematologists Monitor Blood Counts